March 18 (Reuters) - Aurinia Pharmaceuticals Inc AUP.TO :
* Reports fourth quarter and full year 2015 financial results and recent
operational highlights
* Expects that the primary end-point results of the aura trial will be released
in the third quarter ended September 30, 2016
* Reported a consolidated net loss of $4.1 million or $0.13 per common share
for the three months ended December 31, 2015
* Pharma - believes financial resources should be sufficient to finance aura
trial, aurion study, corporate costs until about December 31, 2016
* Qtrly loss per share $0.13
* Future cash requirements could vary from current estimates due to number of
factors including costs associated with aura trial
* Q4 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S
* Source text for Eikon ID:nBw5nDr0ga
* Further company coverage AUP.TO